Holen Sie sich die Stockscreener-App
73.25
4.11%
2.89
Handel nachbörslich:
72.99
-0.26
-0.35%
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
Oppenheimer Maintains Outperform on Nektar Therapeutics (NKTR) March 2026 - Meyka
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Eos Energy Enterprises, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EOSE - GlobeNewswire Inc.
ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Oppenheimer raises Nektar Therapeutics price target to $140 - Investing.com
Nektar Therapeutics (NKTR) PT Raised to $140 at Oppenheimer - StreetInsider
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics - GlobeNewswire
Nektar Q4 Earnings & Revenues Trump Estimates, Pipeline in Focus - TradingView
Nektar Therapeutics (NKTR) Surges After Beating Q4 Expectations - GuruFocus
Nektar Therapeutics stock hits 52-week high at 76.3 USD - Investing.com
Nektar Therapeutics (NASDAQ:NKTR) Q4 2025 Earnings Call Transcript - Insider Monkey
Nektar Therapeutics (NKTR) Reports Q4 and Full Year 2025 Financi - GuruFocus
NKTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - Sahm
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Highlights: Promising Phase 2B Results and ... By GuruFocus - Investing.com Canada
Nektar Therapeutics Reports 2025 Financial Results and Advances Rezpegaldesleukin to Phase 3 for Atopic Dermatitis - Minichart
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Highlights: Pro - GuruFocus
Nektar Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Nektar Therapeutics Q4 2025 shows cash boost and R&D expansion - Investing.com
Nektar (NKTR) Q4 2025 Earnings Call Transcript - AOL.com
Nektar Therapeutics (NKTR) Posts Fourth Quarter Loss, Exceeds Revenue Projections - Bitget
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Nektar (NKTR) Reports Decrease in Q4 Revenue, Prepares for Phase 3 Trials - GuruFocus
Nektar: Q4 Earnings Snapshot - marketscreener.com
Nektar Therapeutics (NKTR) Misses Q4 EPS by 178c - StreetInsider
Nektar Therapeutics Q4 Swings to Loss, Revenue Declines - marketscreener.com
Earnings Flash (NKTR) Nektar Therapeutics Posts Q4 Loss Per Share $1.78, vs. FactSet Est of $2.47 Loss - marketscreener.com
Earnings Flash (NKTR) Nektar Therapeutics Reports Q4 Revenue $21.8M, vs. FactSet Est of $10.2M - marketscreener.com
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - PR Newswire
Securities Fraud Investigation Into Nektar Therapeutics (NKTR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - The AI Journal
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain OfficersNKTR - PR Newswire
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics ... - Bluefield Daily Telegraph
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein - GlobeNewswire
NKTR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Securities Fraud Investigation Into Nektar Therapeutics (NKTR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Carroll County Mirror-Democrat
Nektar Therapeutics Q4 2025 earnings preview - MSN
Nektar Therapeutics Faces Class Action Lawsuit - Intellectia AI
NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
NEKTAR THERAPEUTICS (NKTR) INVESTOR ALERT Investors With - GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure ... - Caledonian Record
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR - ChartMill
FinancialContentPomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR - FinancialContent
Important Notice to Long-Term Shareholders of Boston - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Nektar Therapeutics, Inc. Investors - GlobeNewswire
NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Nektar Therapeutics Sued for Securities Law Violations - Benzinga
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - mydailyrecord.com
Will REZOLVE-AA Class Actions Over Trial Disclosures Change Nektar Therapeutics' (NKTR) REZPEG Narrative? - simplywall.st
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit - PR Newswire
NKTR Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Against Nektar Therapeutics - PR Newswire
Rosen Law Firm Urges Nektar Therapeutics (NASDAQ: NKTR) Stockholders to Contact the Firm for Information About Their Rights - The AI Journal
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Nektar Therapeutics, (NKTR) - TMX Newsfile
303,200 Shares in Nektar Therapeutics $NKTR Acquired by Jefferies Financial Group Inc. - MarketBeat
NKTR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - TMX Newsfile
Nektar Therapeutics stock pops on $300M equity offering - MSN
Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit - PharmiWeb.com
Drugmaker Nektar Faces Suit Over Hair Loss Drug Trial Claims - Law360
Nektar Therapeutics (NKTR) Presents at TD Cowen 46th Annual Health Care ConferenceSlideshow - Seeking Alpha
Three new Nektar hires receive 4,300 stock options in inducement plan - Stock Titan
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):